Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $38.8 million versus the consensus estimate of $38.12 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2024 revenue of $145-155 million, versus the consensus of $152.6 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.